Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blepharitis Clear all
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

NCT04475432
View directory record Official record
Conditions
Blepharitis
Interventions
TP-03, 0.25%, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jul 22, 2026, 12:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lipids of the Human Tear Film and Their Effect on Tear Stability

NCT00803452
View directory record Official record
Conditions
Blepharitis
Interventions
doxycycline, azithromycin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Jul 22, 2026, 12:53 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis

NCT00656539
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 22, 2026, 12:53 AM EDT
Not listed Phase 1 Interventional

A Usability Study of iTEAR100 For Combined EyeLid Microblepharoexfoliation and Neurostimulation

NCT06235450
View directory record Official record
Conditions
MicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye Syndrome
Interventions
iLIDS100
Device
Lead sponsor
Olympic Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Issaquah, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Jul 22, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

NCT05454956
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
Interventions
TP-03, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Northridge, California • Kansas City, Missouri • Cary, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 22, 2026, 12:53 AM EDT
Completed Not applicable Interventional

Corneal Epithelial Stem Cells and Dry Eye Disease

NCT03302273
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye, Ocular Inflammation, Ocular Surface Disease, Ocular Discomfort, Blepharitis
Interventions
Corneal Epithelial Stem Cell Transplant
Other
Lead sponsor
Sloan W. Rush, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Jul 22, 2026, 12:53 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis

NCT01560962
View directory record Official record
Conditions
Blepharitis
Interventions
povidone iodine, No Intervention, Azithromycin, tobramycin-dexmethasone, warm soaked eyelid wash
Drug · Other
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jul 22, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

NCT02218489
View directory record Official record
Conditions
Blepharitis
Interventions
KPI-121, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Jul 22, 2026, 12:53 AM EDT
Completed Phase 4 Interventional

Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

NCT06182358
View directory record Official record
Conditions
Demodex Blepharitis
Interventions
Lotilaner ophthalmic solution, 0.25%, Vehicle control
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Cave Creek, Arizona • Long Beach, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Jul 22, 2026, 12:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome

NCT00344721
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Omega-3 fatty acid supplement, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Jul 22, 2026, 12:53 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Treatment of Anterior Blepharitis With Microblepharoexfoliation Procedure

NCT04290455
View directory record Official record
Conditions
Anterior Blepharitis
Interventions
Microblepharoexfoliative procedure with BlephEx™, Eyelid cleansing with eyelid wipes (Optase), Daily eyelid cleansing with eyelid wipes (Optase)
Device · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jul 22, 2026, 12:53 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

NCT01102244
View directory record Official record
Conditions
Blepharitis
Interventions
Tobradex ST, Azasite
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jul 22, 2026, 12:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of SUMMIT BRUSH in Treatment of Blepharitis

NCT04603222
View directory record Official record
Conditions
Blepharitis
Interventions
SUMMIT BRUSH, Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
Device · Other
Lead sponsor
University of Notre Dame
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Boulder, Colorado • Mishawaka, Indiana • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Jul 22, 2026, 12:53 AM EDT
Completed Not applicable Interventional Results available

Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery

NCT01808560
View directory record Official record
Conditions
Blepharitis, Dry Eye Syndrome
Interventions
LipiFlow Pre-Treatment, LipiFlow Post-treatment
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Hoffman Estates, Illinois • Lake Villa, Illinois • Winchester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Jul 22, 2026, 12:53 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Jul 22, 2026, 12:53 AM EDT
Completed Phase 2 Interventional

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

NCT00894530
View directory record Official record
Conditions
Blepharitis
Interventions
Azithromycin ophthalmic solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
26
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Artesia, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Jul 22, 2026, 12:53 AM EDT
Completed Not applicable Interventional

Comparison of BlephEx to MiBoflo as Treatment Options for Blepharitis

NCT02952079
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye, Posterior Blepharitis
Interventions
Blephex, MiboFlo
Device
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Jul 22, 2026, 12:53 AM EDT